期刊
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
卷 20, 期 11, 页码 1785-1790出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.bbmt.2014.07.010
关键词
Acute myeloid leukemia; Donor lymphocyte infusion; Complete remission
资金
- Ministry of Health, Labour, and Welfare of Japan
- Ministry of Education, Culture, Sports and Technology of Japan
- Ministry of Health, Labour, and Welfare of Japan [H23-010]
- Grants-in-Aid for Scientific Research [24591418] Funding Source: KAKEN
Because the efficacy of donor lymphocyte infusion (DLI) for acute myeloid leukemia (AML) relapse after allogeneic hematopoietic stem cell transplantation (HSCT) remains uncertain, especially in the Asian population, a nationwide registry study was retrospectively performed by the Adult AML Working Group of the Japan Society for Hematopoietic Cell Transplantation to identify the factors affecting the patient survival after DLI. Among 143 adult AML patients who received DLI for the treatment of first hematological relapse after HSCT, the overall survival rates at 1 year, 2 years, and 5 years were 32% +/- 4%, 17% +/- 3%, and 7% +/- 3%, respectively. Complete remission (CR) at the time of DLL which was obtained in 8% of the patients, was the strongest predictive factor for survival after DLL Therefore, long-term survival after DLI was achieved almost exclusively in patients who successfully achieved a CR before DLI, indicating the limited efficacy of DLI in a minority of patients. (C) 2014 American Society for Blood and Marrow Transplantation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据